Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Read more about Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.
Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH. Read more about Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH.
Molecular pathways: targeting ETS gene fusions in cancer. Read more about Molecular pathways: targeting ETS gene fusions in cancer.
To "grow" or "go": TMEM16A expression as a switch between tumor growth and metastasis in SCCHN. Read more about To "grow" or "go": TMEM16A expression as a switch between tumor growth and metastasis in SCCHN.
TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Read more about TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance.
Accelerated approval for pertuzumab in the neoadjuvant setting: winds of change? Read more about Accelerated approval for pertuzumab in the neoadjuvant setting: winds of change?
Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer. Read more about Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.
Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Read more about Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.
The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Read more about The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.
Clusterin is a gene-specific target of microRNA-21 in head and neck squamous cell carcinoma. Read more about Clusterin is a gene-specific target of microRNA-21 in head and neck squamous cell carcinoma.
